Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
- Conditions
- HIV Infections
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT00447902
- Locations
- 🇺🇸
1182.99.31 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇫🇷1182.99.3306K Boehringer Ingelheim Investigational Site, Nantes, France
🇩🇪1182.99.4909 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT00440271
- Locations
- 🇺🇸
1182.98.018 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States
🇺🇸1182.98.014 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1182.98.004 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00431067
- Locations
- 🇺🇸
1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica, California, United States
🇺🇸1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
🇺🇸1200.11.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT00425854
- Locations
- 🇩🇪
1200.10.49006 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany
🇧🇪1200.10.3204 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇩🇪1200.10.49003 Boehringer Ingelheim Investigational Site, Kiel, Germany
Effect of BIBW 2948 BS in COPD
- Conditions
- Pulmonary Disease, Chronic ObstructiveBronchitis, Chronic
- Interventions
- Drug: BIBW 2948 BSDrug: Placebo
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT00423137
- Locations
- 🇺🇸
1219.5.01 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇩🇪1219.5.06 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany
🇺🇸1219.5.04 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
BI 2536 Second Line Monotherapy in SCLC
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT00412880
- Locations
- 🇺🇸
1216.11.003 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1216.11.006 Boehringer Ingelheim Investigational Site, Evanston, Illinois, United States
🇨🇦1216.11.009 Alberta Cancer Board, Edmonton, Alberta, Canada
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 312
- Registration Number
- NCT00402233
- Locations
- 🇺🇸
248.622.5 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸248.622.40 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
🇺🇸248.622.76 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo via corresponding inhaler for blinding purposes
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1480
- Registration Number
- NCT00400153
- Locations
- 🇺🇸
1012.56.01014 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸1012.56.01043 Boehringer Ingelheim Investigational Site, Palo Alto, California, United States
🇺🇸1012.56.01036 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.
- Conditions
- Idiopathic Restless Legs Syndrome
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 154
- Registration Number
- NCT00390689
- Locations
- 🇯🇵
248.627.031 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa, Japan
🇯🇵248.627.037 Boehringer Ingelheim Investigational Site, Aichi-gun, Aichi, Japan
🇯🇵248.627.023 Boehringer Ingelheim Investigational Site, Kitakyusyu, Fukuoka, Japan
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 576
- Registration Number
- NCT00389207
- Locations
- 🇲🇽
1100.1470.55001 Boehringer Ingelheim Investigational Site, Col. Toriello Guerra, Mexico
🇵🇹1100.1470.35103 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇨🇭1100.1470.41002 Boehringer Ingelheim Investigational Site, Zürich, Switzerland